Loading clinical trials...
Loading clinical trials...
As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled s...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT05746039 · Obesity, Interstitial Lung Disease, and more
NCT07218029 · Pulmonary Arterial Hypertension
NCT07073820 · Pulmonary Hypertension
NCT03854071 · Heart Failure, Pulmonary Hypertension, and more
NCT07477197 · Adult Congenital Heart Disease, Pulmonary Hypertension, and more
Pfizer Investigational Site
Fountain Valley, California
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Weston, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions